Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost

JPMorgan upgraded Phibro Animal Health (PAHC) citing strong execution following its $350 million acquisition of Zoetis' medicated feed additive portfolio, which is expected to enhance profitability and be accretive to adjusted EPS. While Q3 FY2025 sales narrowly missed consensus, the company reported adjusted EPS of $0.63, significantly beating estimates, and subsequently raised its full-year FY2025 adjusted EPS guidance. Analysts anticipate continued healthy growth in key product segments for FY2026, driven by robust livestock sector fundamentals and an attractive valuation, leading to an 8.57% surge in PAHC's stock.

Analysis

JPMorgan has upgraded Phibro Animal Health (PAHC) based on the strong execution of its $350 million acquisition of Zoetis' medicated feed additive portfolio, a deal expected to be accretive to adjusted earnings per share and enhance EBITDA margins. This positive outlook is substantiated by the company's third-quarter fiscal 2025 performance, where it delivered adjusted EPS of $0.63, significantly beating the consensus of $0.52. Consequently, PAHC raised its full-year adjusted EPS guidance to $1.96-$2.09, above the prior consensus of $1.94. While Q3 sales of $347.8 million, a 32% year-over-year increase, narrowly missed estimates, the company's revised annual sales guidance of $1.26 billion-$1.29 billion aligns with market expectations. The analyst upgrade, which catalyzed an 8.57% rise in PAHC's stock, underscores the view that despite the recent rally, the company's valuation remains attractive, supported by strong fundamentals in the livestock sector and anticipated growth across its key product segments into fiscal 2026.

Key Decisions for Investors

• Investors should consider the analyst upgrade and strong earnings beat as a positive signal, supporting a constructive outlook on Phibro Animal Health's growth trajectory.
• Monitor future earnings reports for evidence of the projected EBITDA margin expansion and EPS accretion from the Zoetis portfolio integration, as this is central to the bull thesis.
• Despite the stock's recent 8.57% appreciation, the analyst's view of a still-attractive valuation suggests that long-term investors may find current levels viable, while more cautious investors might await a consolidation period.
• Pay close attention to top-line growth in subsequent quarters to ensure the minor Q3 sales miss was an anomaly and that the acquisition is translating into sustained revenue momentum.